[ad_1]
At a turning point in the pandemic, Commission President Ursula von der Leyen presented important and positive developments in the field of vaccines at the Euro-conference on Pandemics. As you said, the EU could even approve two coronavirus vaccines this year.
The President of the Commission stated that the purchase contracts with 5 pharmaceutical companies (BioNTech, Curavac Astra Zeneca, Johnson & Johnson, Sanofi) have already been finalized and that negotiations are under way for another two (Moderna, Novavax).
All vaccines will be thoroughly tested prior to licensing and relevant European services are in daily contact with others, such as the US.
“If all goes well, the European Medicines Agency (EMA) tells us that the marketing authorization for BioNTech and Moderna can be granted from the second half of December 2020.” said Ursula von der Leyen.
Good discussion with leaders. the @EU_Commission is expanding its vaccine portfolio, with ongoing discussions with Moderna & Novavax.
We will continue to coordinate our efforts to keep citizens informed about vaccination and safety.https: //t.co/vUMEQjWFT6
– Ursula von der Leyen (@vonderleyen) November 19, 2020
European Council President Charles Michel said recent vaccine test results were encouraging and it was agreed to speed up national vaccination programs to make them accessible to all European citizens when approved.
The European authorities – Michel added – have already concluded several purchase agreements. “There will be challenges in storage, transportation and quantity of doses,” he said. He also acknowledged that another problem is communication, referring to the “growing number” of those who are skeptical of vaccines.
Pfizer and BioNTech are expected to request an urgent authorization from the United States Food and Drug Administration (FDA) tomorrow Friday for the vaccine they are developing against the COVID-19 infection.
At least that’s what the CEO of BioNTech said in an exclusive statement to the US news network CNN, Ugur Sahin.
According to him, the two partners will submit all the necessary documents for the license application following yesterday’s announcement of the final results of Phase 3 of the BNT162b1 clinical trials, which demonstrate that they are 95% effective in preventing COVID-19 infection, even in the elderly, without causing serious side effects.
The head of research for the Oxford and AstraZeneca vaccine researchers said the scientists were very satisfied with the results given earlier in the post, noting that there is extremely good tolerance to the vaccine on the part of those who are over 55.
European leaders considered today’s teleconference extremely crucial for the future of the EU which, in addition to the second wave of the pandemic, which affects all Member States, They are called to find a solution to the great political and, above all, economic problem, which causes the veto of Hungary and Poland in the approval of the community budget for the period 2021-2027.
News Today
Mitsotakis at the Summit: Slowly and carefully opening with a view to Christmas
‘Battle’ for 200 Covid-19 beds in Thessaloniki: doctors say ‘no’ to the ministry’s request
SW: The photo with the students was taken by the community leader and owner of the cafe.
[ad_2]
